Denali Therapeutics Inc. business relationships
Companies named in Denali Therapeutics Inc.’s 10-K filed 2026-02-26, and public companies whose annual reports name Denali Therapeutics Inc.. Each link shows the sentence it came from. Scores are Engagemii’s AI visibility scores.
- AEO visibility
- 6.1 / 10
- AI naming
- 92 / 100 Top 1% in its category
- Agent readiness
- 25 / 100
- AI adoption
- 0 / 100
Named in Denali Therapeutics Inc.’s annual report 14
“The Company also believes that Takeda meets the definition of a customer as defined in ASC 606, Revenue From Contracts With Customers for the PTV:PGRN Technology License performance obligation delivered in the collaboration agreement.” SEC filing
“The side letter also effected the immediate termination of the ROFN and Option Agreement; as such, we expect to receive no future milestone or royalty payments from Biogen related to the ATV:Abeta program.” SEC filing
“We and Takeda may each terminate the Takeda Collaboration Agreement in its entirety if the other party is declared insolvent or in similar financial distress or if, subject to a specified cure period, the other party challenges any patents licensed to it under the Takeda Collaboration Agreement.” SEC filing
“The Provisional Biogen Collaboration Agreement expired in October 2020 upon the execution of a Definitive LRRK2 Collaboration and License Agreement ("LRRK2 Agreement") with Biogen on October 4, 2020 and a Right of First Negotiation, Option and License Agreement (the "ROFN and Option Agreement") on O...” SEC filing
“As described in more detail in "Business - Licenses and Collaborations" below, we are collaborating with Biogen on the Peripheral LRRK2 program.” SEC filing
“We have an active collaboration with Takeda Pharmaceutical Company Limited ("Takeda") for the development and commercialization of TAK-594/DNL593 (PTV:PGRN) for FTD- GRN .” SEC filing
“Subsequent to this side letter, the Company expects to receive no future milestone or royalty payments from Sanofi related to the CNS Products program.” SEC filing
“Sanofi Collaboration and License Agreement” SEC filing
“Our RIPK1 program is subject to our collaboration agreement with Sanofi.” SEC filing
“In addition, the Company became a direct licensee of certain intellectual property of F-star Biotechnology Limited ("F-Star Ltd") by way of the Company's assumption of F-star Gamma's license agreement with F-star Ltd, dated August 24, 2016, (the "F-star Gamma License").” SEC filing
“Following expiration of the agreement, we will retain our licenses under the intellectual property Genentech licensed to us on a non-exclusive, royalty-free basis.” SEC filing
“In June 2016, we entered into an exclusive license agreement with Genentech.” SEC filing
“Our collaboration partner in the LRRK2 program, Biogen, is responsible for 50% of any payment obligation to Genentech under the Biogen Collaboration Agreement.” SEC filing
“If one of our licensed products incorporates a compound provided to us by Genentech, has orphan drug exclusivity, and is not covered by a valid claim of a licensed patent, we must pay royalties on net sales of such licensed products on a country-by-country and licensed product-by-licensed product ba...” SEC filing
Companies whose annual reports name Denali Therapeutics Inc. 3
“| Denali Therapeutics | | U.S. | | Strategic option and collaboration agreement to develop and commercialize up to three specified therapeutic product candidates for neurodegenerative diseases, incorporating Denali's transport vehicle (TV) platform for increased exposure of biotherapeutic products i...” SEC filing
“• Denali Therapeutics Inc. (2018): collaboration agreement on the development of multiple molecules with the potential to treat” SEC filing
“Denali Therapeutics Inc., in partnership with Takeda Pharmaceutical Company Limited, is conducting a Phase 1/2 clinical trial for their recombinant progranulin protein.” SEC filing
Links are read automatically from SEC annual reports (10-K, 20-F, 40-F). In a hand check of random links, about 8 in 10 were real business relationships, so every link carries its source sentence.